The New Year is often a time of change. It’s a period when we emerge from the excesses of the holidays and embrace New Year’s resolutions – eat better, work out more, be more financially responsible – whether we stick to them is another matter! 2026 looks set to be a time of change for the pharmaceutical industry, too, with artificial intelligence (AI) the chief catalyst. We’ve compiled the views of Within3 experts and combined them with external survey results to produce a list of AI predictions for the pharma industry in 2026.
You can read the first five below. Want the full list of predictions and accompanying industry data? Read our 2026 predictions report [here].
1) AI will eliminate manual insight reporting
Insights reporting has always been a time-consuming and labor-intensive process that takes effort away from high-value strategic tasks. In years to come, these repetitive manual reporting tasks will be automated by AI – with purpose-built pharma AI systems forming an intelligent layer on top of teams’ existing systems. This view is shared by pharma industry leaders, 47% of whom see ‘reducing manual reporting and analytics work’ as the area where AI will have the greatest impact in 2026, according to our latest poll results.
“Reporting is rarely anyone’s full-time job. The more AI takes on that burden, the more people can get back to doing the work that really matters.”
– Samantha McAloney, Senior Vice President of Product Management, Within3
2) AI will transform static planning into adaptive strategy
According to Impatient Health, “commercial teams don’t actually do launch strategy – not as any other industry would recognize it.” What they tend to do instead is plan. Teams address the ‘when’ and the ‘how’ of launching a new therapy before ever considering the what and the why – if they ever get there at all. Planning without strategy means teams struggle to pivot when market forces change.
AI is poised to address this issue, empowering teams with predictive modelling so they can fully understand the markets they’re launching into and anticipate changing HCP and patient trends. “In 2024, this was science fiction,” says Within3 CEO and Founder Lance Hill. “In 2025, it became possible. By 2026, it will be accomplished.” Only 10% of companies currently use real-time data to guide launch strategies, according to our survey results. The next year will see that percentage grow significantly.
3) AI will enable instantaneous market responses
By this time next year, not only will teams be empowered to better understand pharmaceutical markets, they’ll have those insights at their fingertips in moments. AI will cut through pharma’s data silos by combining field activity, social sentiment, claims data and more into a single, real-time market view. This visibility will allow launch teams to respond to market shifts practically instantaneously, granting them the agility to confidently adapt their strategies before they lose their competitive advantage.
Tony Page, Senior Vice President of Insight Analytics at Within3, expects this to create a ‘haves and have-nots’ dynamic among pharma launch teams.
“Your ability to leverage AI directly determines the trajectory of your launch. If you don’t adopt it, someone else will – and they’ll take your market share.”
– Tony Page, Senior Vice President of Insight Analytics, Within3
4) AI will predict sentiment shifts before they occur
Social listening has proven a valuable tool for hearing what the market is saying, and for tracking HCP and patient sentiments. That tells you what has happened. In 2026, AI will be able to tell you what will happen. By contextualizing sentiment data across a variety of sources, AI will become capable of predicting patient, HCP, and competitor sentiment shifts long before they occur.
“Standalone social listening tools are fine, but they’re already becoming obsolete unless integrated into a broader market model.”
– Lance Hill, CEO, Within3
We’ve seen how this can work across other industries, with content streaming platforms using predictive sentiment analytics to reduce their viewer drop-off rates by 30%.
5) AI will amplify the patient voice
AI is poised to help the pharma industry become increasingly patient-centric. By analyzing vast quantities of social media data, advocacy data, and digital dialogue, AI will be capable of surfacing patient trends and sentiments that would otherwise have gone unnoticed. Moving forward, pharma companies will be able to consider these insights in their launch strategies and address unmet needs more effectively.
“Increased accessibility to patient data will help bring the patient voice closer to the center of decision-making.”
– Amanda Sweeney, Senior Vice President of Client Success, Within3
Crucially, pharma companies will be able to put a dollar value on these insights – hearing the patient voice not only opens up new commercial opportunities, but also allows them to minimize redundancies and make commercial programs more efficient.
Attempting to predict the future can leave you open to ridicule, but these are not idle speculations. These predictions are things that will happen – the only question is the timeline. While the early adopters might tick one or several of these predictions off their lists in 2026, it may take 5–10 years for these trends to become industry standards. So, will you adopt Launch Intelligence™ and start repeating the benefits, or wait until the early adopters have already pulled ahead?
If you’d like to read the rest of our 2026 AI predictions and supporting industry data, you can access the full report [here].
